Fluoxetine for stroke recovery improvement - The doubleblind, randomised placebo-controlled FOCUS-Poland trial

Neurologia i Neurochirurgia Polska

Volumn 54, Issue 6, 2020, Pages 544-551

  Bembenek, Jan P ^a   Niewada, Maciej ^b   Klysz, Bozena ^a   Mazur, Anna ^a   Kurczych, Katarzyna ^a   Gluszkiewicz, Marcin ^a   Czlonkowska, Anna ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Acute stroke; Fluoxetine; Motor recovery; Stroke outcome

Indexed keywords

FLUOXETINE; PLACEBO;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; FRACTURE; FUNCTIONAL STATUS; HAND FUNCTION; HUMAN; INFORMATION PROCESSING; MALE; MOTOR PERFORMANCE; ODDS RATIO; ONSET AGE; POLAND; POST-STROKE DEPRESSION; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; TREATMENT OUTCOME; CONVALESCENCE;

DOUBLE-BLIND METHOD; FLUOXETINE; HUMANS; POLAND; RECOVERY OF FUNCTION; STROKE; TREATMENT OUTCOME;

EID: 85099428746     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.5603/PJNNS.A2020.0099     Document Type: Article

References (28)

1. Katan M, Luft A. Global Burden of Stroke. Semin Neurol. 2018; 38(2): 208-211, doi: 10.1055/s-0038-1649503, indexed in Pubmed: 29791947.
2. Robinson RG, Jorge RE. Post-Stroke Depression: A Review. Am J Psychiatry. 2016; 173(3): 221-231, doi: 10.1176/appi. ajp.2015.15030363, indexed in Pubmed: 26684921.
3. Lim CM, Kim SW, Park JY, et al. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res. 2009; 87(4): 1037-1045, doi: 10.1002/jnr.21899, indexed in Pubmed: 18855941.
4. Wang JW, David DJ, Monckton JE, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008; 28(6): 1374-1384, doi: 10.1523/JNEUROSCI. 3632-07.2008, indexed in Pubmed: 18256257.
5. McCann SK, Irvine C, Mead GE, et al. Efficacy of antidepressants in animal models of ischemic stroke: A systematic review and meta-analysis. Stroke. 2014; 45(10): 3055-3063, doi: 10.1161/STROKEAHA. 114.006304, indexed in Pubmed: 25184357.
6. Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): A randomised placebo-controlled trial. Lancet Neurol. 2011; 10(2): 123-130, doi: 10.1016/S1474-4422(10)70314-8, indexed in Pubmed: 21216670.
7. Gu SC, Wang CD. Early Selective Serotonin Reuptake Inhibitors for Recovery after Stroke: A Meta-Analysis and Trial Sequential Analysis. J Stroke Cerebrovasc Dis. 2018; 27(5): 1178-1189, doi: 10.1016/j. jstrokecerebrovasdis.2017.11.031, indexed in Pubmed: 29276014.
8. Legg LA, Tilney R, Hsieh CF, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2019; 2019(11): E142-e143, doi: 10.1002/14651858.CD009286.pub3, indexed in Pubmed: 31769878.
9. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): A pragmatic, double-blind, randomised, controlled trial. Lancet. 2019; 393(10168): 265-274, doi: 10.1016/S0140-6736(18)32823-X, indexed in Pubmed: 30528472.
10. AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020; 19(8): 651-660, doi: 10.1016/S1474-4422(20)30207-6, indexed in Pubmed: 32702334.
11. EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020; 19(8): 661-669, doi: 10.1016/S1474-4422(20)30219-2, indexed in Pubmed: 32702335.
12. Mead G, Hackett ML, Lundström E, et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: A study protocol for three multicentre randomised controlled trials. Trials. 2015; 16: 369, doi: 10.1186/s13063-015-0864-1, indexed in Pubmed: 26289352.
13. Brott T, Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: A clinical examination scale. Stroke. 1989; 20(7): 864-870, doi: 10.1161/01.str.20.7.864, indexed in Pubmed: 2749846.
14. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991; 337(8756): 1521-1526, doi: 10.1016/0140-6736(91)93206-o, indexed in Pubmed: 1675378.
15. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24(1): 35-41, doi: 10.1161/01.str.24.1.35, indexed in Pubmed: 7678184.
16. Broderick JP, Adeoye O, Elm J. Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. Stroke. 2017; 48(7): 2007-2012, doi: 10.1161/STROKEAHA.117.017866, indexed in Pubmed: 28626052.
17. Duncan PW, Wallace D, Lai SM, et al. The stroke impact scale version 2.0. Evaluation of reliability, validity, and sensitivity to change. Stroke. 1999; 30(10): 2131-2140, doi: 10.1161/01.str.30.10.2131, indexed in Pubmed: 10512918.
18. Dyck PJ, Boes CJ, Mulder D, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst. 2005; 10(2): 158-173, doi: 10.1111/j.1085-9489.2005.0010206.x, indexed in Pubmed: 15958127.
19. Brunnstrom S. Movement therapy in hemiplegia: A neurophysiological approach. New York: Harner and Row Publish. ; 1970.
20. Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. Md State Med J. 1965; 14: 61-65, indexed in Pubmed: 14258950.
21. Hoeymans N, Garssen AA, Westert GP, et al. Measuring mental health of the Dutch population: A comparison of the GHQ-12 and the MHI-5. Health Qual Life Outcomes. 2004; 2: 23, doi: 10.1186/1477-7525-2-23, indexed in Pubmed: 15132745.
22. McCabe CJ, Thomas KJ, Brazier JE, et al. Measuring the mental health status of a population: A comparison of the GHQ-12 and the SF-36 (MHI-5). Br J Psychiatry. 1996; 169(4): 516-521, doi: 10.1192/bjp.169.4.516, indexed in Pubmed: 8894205.
23. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10): 1727-1736, doi: 10.1007/s11136-011-9903-x, indexed in Pubmed: 21479777.
24. Tsapakis EM, Gamie Z, Tran GT, et al. The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry. 2012; 27(3): 156-169, doi: 10.1016/j.eurpsy.2010.10.006, indexed in Pubmed: 21295451.
25. Wadhwa R, Kumar M, Talegaonkar S, et al. Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms. Osteoporos Sarcopenia. 2017; 3(2): 75-81, doi: 10.1016/j. afos.2017.05.002, indexed in Pubmed: 30775508.
26. Myint PK, Poole KES, Warburton EA. Hip fractures after stroke and their prevention. QJM. 2007; 100(9): 539-545, doi: 10.1093/qjmed/hcm067, indexed in Pubmed: 17693418.
27. Douros A, Dell'Aniello S, Dehghan G, et al. Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study. Neurology. 2019; 93(10): E1010-e1020, doi: 10.1212/WNL.0000000000008060, indexed in Pubmed: 31391245.
28. Jensen MP, Ziff OJ, Banerjee G, et al. The impact of selective serotonin reuptake inhibitors on the risk of intracranial haemorrhage: A systematic review and meta-analysis. Eur Stroke J. 2019; 4(2): 144-152, doi: 10.1177/2396987319827211, indexed in Pubmed: 31259262